GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
2.1210
-0.0390 (-1.81%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.1600
Open2.1600
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.9100 - 2.1600
52 Week Range0.0838 - 3.2800
Volume163,467
Avg. Volume109,640
Market Cap137.396M
Beta (3Y Monthly)-2.91
PE Ratio (TTM)9.30
EPS (TTM)0.2280
Earnings DateSep 17, 2019 - Sep 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    Generex Biotechnology Reiterates 1:1 Stock Dividend for Clarity in the Market and Provides Details on Capital Structure

    Generex Biotechnology Corporation (www.generex.com) (GNBT) today provided additional guidance for investors on the company’s plans for the GNBT up-list to Nasdaq and the payment of the 1:1 share dividend to shareholders. Due to high call volume and ongoing confusion in the market related to the upcoming 1:1 stock dividend, we would like to reiterate the terms of the dividend to be paid to shareholders.

  • GlobeNewswire

    Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (“Generex”) is pleased to announce that Generex has acquired an additional 38% of Olaregen Therapeutix for a total Generex ownership of approximately 99% after the share exchange at $2.50 a share for GNBT stock, in a cashless transaction. Also, Generex is pleased that today it paid the final payment of $138,000 to a noteholder to satisfy an outstanding note, which together with the payment of $900,000 on Friday August 16, clears over $1 million in debt from the books to further strengthen the Generex balance sheet as the Nasdaq up-list application is being processed. Joseph Moscato, Generex President & Chief Executive Officer stated, “We are thrilled to acquire an additional 38% of Olaregen as we launch ExcellagenÒ into the marketplace.

  • GlobeNewswire

    Generex Biotechnology Announces Plans for NuGenerex Immuno-Oncology Spinout through a Targeted Acquisition of a Public Company and Planned Merger with Kiromic

    Generex Biotechnology (www.generex.com) (GNBT) today announced that the Company has identified a public, development stage company that is fully reporting and current on its filings with the SEC, and DTC eligible that will serve as a vehicle for the spin-out of its subsidiary NuGenerex Immuno-Oncology (NGIO) as a separate public company. Generex is in final negotiations to retain the controlling interest of the outstanding shares of the acquisition target and expects to complete the contracts and file a super 8K in the coming weeks. Generex and its shareholders who have received the 1:4 NGIO dividend will initially hold 100% of the NGIO shares following the acquisition, which will set the stage for the subsequent planned merger with Kiromic.

  • GlobeNewswire

    Generex Biotechnology Defines 1:1 Stock Dividend and Provides Details on Capital Structure

    Generex Biotechnology Corporation (www.generex.com) (GNBT) today provided additional guidance for investors on the company’s plans for the GNBT up-list to Nasdaq and the payment of the 1:1 share dividend to shareholders. Due to high call volume and ongoing confusion in the market related to the upcoming 1:1 stock dividend, we would like to reiterate the terms of the dividend to be paid to shareholders.

  • GlobeNewswire

    Generex Biotechnology Announces Update to the Previously Declared 1:1 Stock Dividend

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (“Generex”) today announced that it was proceeding with the dividend in anticipation of listing on Nasdaq. The Company remains optimistic in its ability to list on Nasdaq and with the confusion by the shareholders on the pay date, Generex wanted to provide its shareholders with a definitive Pay Date.

  • GlobeNewswire

    Generex News Alert: Generex to Announce Positive Shareholder News on Monday August 12, 2019 at 8 AM Payment Details for the 1:1 GNBT Stock Dividend

    MIRAMAR, Fla., Aug. 09, 2019 -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today provided a news alert for GNBT shareholders that the Company.

  • GlobeNewswire

    Generex Biotechnology Announces Interview with President & CEO Joe Moscato

    During the interview, Mr. Moscato spoke about the recent acquisitions of MediSource Partners and Pantheon Medical, the launch of Excellagen by Generex’ subsidiary Olaregen, and the Generex corporate strategy of building specialty networks to provide end-to-end, patient centric solutions that enhance the doctor/patient relationship. Mr. Moscato also spoke about the planned Nasdaq up-list and the associated 1:1 dividend. “My entire focus is on building value for our shareholders through execution on our strategy at Generex.

  • GlobeNewswire

    Generex Biotechnology Welcomes MediSource Partners to the NuGenerex Family of Companies

    Generex Biotechnology Corporation (www.generex.com) (GNBT) is pleased to welcome MediSource Partners (https://medisourcepartners.com) to the NuGenerex family of subsidiary companies. MediSource is a national distributor of medical devices, orthopedic implants, surgical kits, and biologics and cellular tissue products (C/TPs). Additionally, MediSource has built a national network of partner organizations through which to broker mutually beneficial deals between healthcare providers and partners in the network to structure and implement value added agreements that reduce costs and increase efficiency.

  • GlobeNewswire

    Generex Biotechnology Introduces Pantheon Medical, the Newest Member of the NuGenerex Family of Companies

    Generex Biotechnology Corporation (www.generex.com) (GNBT) is proud to introduce Pantheon Medical (https://pantheonortho.com) as the newest member of the NuGenerex family of subsidiary companies. Pantheon is a manufacturer of orthopedic foot & ankle surgery kits that offer physician friendly “all-in-one,” integrated surgical kits that include plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. The number of orthopedic surgeries, including hip & knee replacements, ankle & foot repairs and corrections, and fracture repairs continue to climb due to the aging population and the increased prevalence of obesity, which can lead to joint problems, particularly in the lower extremities.

  • GlobeNewswire

    Generex Biotechnology Provides Guidance on 1:1 Stock Dividend

    Joseph Moscato, Generex President & Chief Executive Officer stated, “Many thanks to our shareholders and interested parties for participating in our conference call last Thursday, July 25. Since then, I have received a number of calls pertaining to the 1:1 shareholder dividend, so I want to provide some clarity with this release.

  • GlobeNewswire

    Generex Biotechnology Provides a Summary of Its Investor Conference Call Held on July 25, 2019

    Generex Biotechnology Corporation (www.generex.com) (GNBT) today provided a summary of the investor conference call held yesterday, July 25, 2019 at 4:00 pm during which Joseph Moscato, Generex President & Chief Executive Officer updated investors on the company’s plans for the GNBT up-list and the previously declared 1:1 share dividend.  He also provided guidance on the proposed timing for the NuGenerex Immuno-Oncology (NGIO) spinout and subsequent planned merger with Kiromic. Mr. Moscato stated: “Many thanks to our shareholders and interested parties for calling in yesterday to hear about our progress in achieving stage 3 of our plan to bring Generex back to the Nasdaq.

  • GlobeNewswire

    Reminder: Investor Conference Call Today July 25, 2019 Management to Provide Details on Generex Up-list and 1:1 Stock Dividend

    MIRAMAR, Fla., July 25, 2019 -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following.

  • GlobeNewswire

    Generex Biotechnology Announces Satisfaction of Debt Obligation

    Retires $3,150,972 in debt and satisfies all associated obligationsPayment in GNBT restricted common shares at the July 16, 2019 closing price MIRAMAR, Fla., July 19, 2019 --.

  • GlobeNewswire

    Generex Biotechnology Announces Investor Conference Call Scheduled for July 25, 2019

    MIRAMAR, Fla., July 16, 2019 -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Thursday July.

  • GlobeNewswire

    Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors APMA Annual Scientific Meeting

    Olaregen Silver SponsorshipDr. Lois Chandler, PhD Presents Excellagen Research as Keynote Speaker at Wound Care SymposiumRapid Acceleration of Healing with Wound Conforming,.

  • GlobeNewswire

    Generex Biotechnology Announces Closing on Acquisition of MediSource Partners

    Generex Biotechnology Corporation (GNBT) is pleased to announce the Company has completed the acquisition agreement to acquire assets and operations of Medisource Partners, an FDA-registered distributor of medical and surgical products including bone grafts and biologics from a range of surgical product manufacturers. Under the terms of the deal, Generex will acquire 100% of the assets of Medisource including business operations, accounts receivable and inventory, contracts, and real estate, in an all-stock transaction, effective August 1, 2019, following the close of Generex’ fiscal year.

  • GlobeNewswire

    Generex Biotechnology Announces Acquisition of Pantheon Medical Foot & Ankle

    Generex Biotechnology Corporation (GNBT) is pleased to announce that the company has completed the acquisition of Pantheon Medical – Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools. Under the terms of the deal, Generex will acquire all of the assets of Pantheon Medical including business operations, accounts receivable and inventory, contracts, real estate, and an FDA letter related to balanced plating system, on a debt free basis, in a non-cash transaction with Generex (GNBT) stock, plus additional cash and stock consideration upon achieving certain sales and profit goals.

  • GlobeNewswire

    Generex Biotechnology Provides Fiscal Year Overview

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided an overview of Generex’s accomplishments for the fiscal year ending on July 31, 2019, as outlined herein. As the foundation for the reorganization, we are acquiring operating companies that provide multiple and significant revenue streams through delivery of patient-focused healthcare products and services, including specialty pharmacy, orthopedic implants, surgical supplies, biologics, medical devices, and regenerative medicines.

  • GlobeNewswire

    Generex Engages Donohoe Advisory to Assist with Uplisting

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Generex has engaged Donohoe Advisory Associates LLC (“Donohoe Advisory”) in connection with its efforts to seek a listing for its common shares on a national securities exchange. Donohoe Advisory was founded by Dave Donohoe in 2004, and since that time the firm has successfully represented nearly 1,000 companies in a wide range of listing matters at both The Nasdaq Stock Market (“Nasdaq”) and the New York Stock Exchange (the “NYSE”). Each professional member of Donohoe Advisory’s team previously worked for either Nasdaq or the NYSE.  Prior to forming Donohoe Advisory, Dave Donohoe spent 9+ years with Nasdaq, where he ultimately served as Chief Counsel in the Listing Qualifications Department.

  • Newsfile

    The Stock Day Podcast Hosts Generex Biotechnology Corporation to Discuss Uplisting on the NASDAQ

    Phoenix, Arizona--(Newsfile Corp. - July 1, 2019) - The Stock Day Podcast welcomed Generex Biotechnology Corporation (OTCQB: GNBT) ("the Company"), an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. CEO and President, Joseph Moscato, joined Stock Day host Everett Jolly.Jolly began the interview by asking Moscato for an update on the Company's recent projects. Moscato explained that the Company has made a few ...

  • GlobeNewswire

    Generex Announces Update on 1:1 Dividend and NASDAQ Listing

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on the previously announced 1:1 GNBT stock dividend.  After discussing our listing with Nasdaq officials and our transfer agent Broadridge Financial Solutions, Inc., the dividend will be paid the day after our listing to the Nasdaq stock exchange, not on the same day as the listing as previously stated. Joe Moscato, President & Chief Executive Officer of Generex stated, “We are very close to submitting our application to Nasdaq for the up-list, and we have gotten positive input and direction from Nasdaq officials. The listing on the Nasdaq exchange is the last piece in our overall plan we put forth in January 2017 and ends with our 1:1 dividend to shareholders after we are listed.  We are excited about the potential listing on Nasdaq, which will ensure our future and provide Generex with a significant benefit as it relates to raising capital and investor liquidity while building sustainable value for our shareholders.

  • GlobeNewswire

    Generex Biotechnology Subsidiary Olaregen Therapeutix Receives American Podiatry Medical Associations “Seal of Approval” for Excellagen Wound Conforming Matrix

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), announced today that their subsidiary, Olaregen Therapeutix, Inc., received the prestigious “Seal of Approval” from the American Podiatric Medical Association (APMA) for their Cellular Tissue Product, Excellagen Wound Conforming Matrix. Founded in 1912, the APMA is the leading resource for foot and ankle health information. The APMA Seal of Approval/Acceptance Program evaluates the use of therapeutic agents and their adjuncts (pharmaceuticals) and regulated medical devices.

  • GlobeNewswire

    Generex Signs Letter of Intent with Kiromic to Merge with NuGenerex Immuno-Oncology Forming a Multi-Platform Clinical Stage Immunotherapy Company

    Generex Biotechnology Corporation (“Generex”) (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that Generex has signed a Letter of Intent (“LOI”) with Kiromic, Inc., a clinical stage immunotherapy company (“Kiromic”), to merge into a newly formed Generex entity, called NuGenerex Immuno-Oncology, in an all-stock transaction. With the merger, NuGenerex Immuno-Oncology will house both Kiromic and our subsidiary Antigen Express, Inc., which is developing AE37 in combination with check point inhibitors for the treatment of triple negative breast cancer. Kiromic, which is collaborating with MD Anderson Cancer Center, has multiple patented proprietary immuno-oncology platforms, including CAR-T, CAR NK, an oral vaccine delivery system, and DIAMOND AI, an artificial intelligence system with a multifaceted predictive algorithm that combines genomic sequencing, proteomic analysis, and clinical data to identify novel tumor mutations that can be targeted with immunotherapy.

  • GlobeNewswire

    Generex Investor Conference Call Recording Now Available Online Detailing 1:1 Stock Dividend, Merger for NuGenerex Immuno-Oncology and Go Forward Plans

    The call updated investors on the previously announced 1:1 dividend that will be paid to shareholders upon up-list to the NASDAQ national stock exchange. Joseph Moscato, Generex President & Chief Executive Officer, discussed the company’s accomplishments including the launch of Excellagen® wound conforming matrix by subsidiary Olaregen Therapeutix, the reorganization of NuGenerex Distribution Solutions’ MSO model, the potential merger of NuGenerex Immuno-Oncology with Kiromic, a multi-platform immunotherapeutic company, and the launch of our new businesses NuGenerex Chronic Care Solutions (NCCS) and NuGenerex Health, as well as the strategic focus of Generex for 2019 and beyond. Mr. Moscato commented, “As we discussed on Friday’s call, Generex has made significant strides toward achieving our goal of bringing Generex back to a national exchange.

  • GlobeNewswire

    Generex Announces That the Pool Shares for the Benefit of Generex Will Be Retired and Put Back into the Corporate Treasury Following Payment of the 1:1 Dividend

    MIRAMAR, Fla., June 21, 2019 -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the “Pool”.